Citadel Advisors
SPRB

Citadel Advisors’s Spruce Biosciences SPRB Stock Holding History

Citadel Advisors’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15
Closed -$522 – 15613
2024
Q3 		$522 Sell
15
-622
-98% -$22.8K ﹤0.01% 14002
2024
Q2 		$24.7K Buy
637
+328
+106% +$17.6K ﹤0.01% 12449
2024
Q1 		$18.2K Buy
+309
New +$78.6K ﹤0.01% 13071

Other funds holding SPRB

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Citadel Advisors's SPRB Position: Q1 2026 in Review

Citadel Advisors held its Spruce Biosciences (SPRB) position steady in Q1 2026 at 69,999 shares worth $4.57M. The position accounts for ﹤0.01% of the portfolio, ranked #4491.

Citadel Advisors first reported a position in SPRB in Q4 2020 and has held it in 18 quarters since. The position peaked at $41.4M in Q4 2020. 32 funds tracked by Wall St. Rank hold SPRB as of Q1 2026.

  • Citadel Advisors held 69,999 shares of Spruce Biosciences worth $4.57M as of Q1 2026.
  • Citadel Advisors left its Spruce Biosciences share count unchanged in Q1 2026.
  • Spruce Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4491 holding.
  • Citadel Advisors first reported a position in Spruce Biosciences in Q4 2020 and has held it in 18 quarters since.
  • Citadel Advisors's Spruce Biosciences position peaked at $41.4M in Q4 2020.
  • 32 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.